FDA extends review period for Humacyte’s vascular trauma treatment ATEV
The U.S. Food and Drug Administration’s review of Humacyte, Inc.'s innovative vascular trauma treatment, known as the acellular tissue engineered vessel (ATEV), has hit an ... Read More
Humacyte to merge with Alpha Healthcare Acquisition Corp in $1.1bn deal to advance regenerative medicine
Humacyte, Inc., a clinical-stage biotech company based in Durham, North Carolina, has announced a merger with Alpha Healthcare Acquisition Corp. (AHAC), a blank check company. ... Read More